Status:
NOT_YET_RECRUITING
Proteomic Analysis of Amniotic Fluid to Predict Postnatal Renal Function in Fetuses With Renal and Urinary Tract Malformations
Lead Sponsor:
University Hospital, Toulouse
Conditions:
Kidney Diseases
Eligibility:
FEMALE
Phase:
NA
Brief Summary
The aim of this project is to validate a previously established amniotic fluid 98 peptide signature predictive of post-natal outcome in fetuses with congenital anomalies of the kidney and the urinary ...
Detailed Description
CAKUT represent 20-30% of all inborn malformations. Whereas prognosis is generally favorable in unilateral disease, bilateral CAKUT are the predominant causes of chronic kidney disease (CKD) in childh...
Eligibility Criteria
Inclusion
- All fetuses with bilateral renal development anomalies with structural changes in the parenchyma, with or without associated urinary tract anomalies;
- Signed informed consent of the mother
- Non-opposition of the father.
Exclusion
- Unilateral abnormality of renal development
- Any pregnancy for which amniocentesis may represent a risk for the fetus or the mother
- Twin pregnancies
- Pregnant woman protected by law (guardianship, curatorship)
Key Trial Info
Start Date :
April 15 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 20 2029
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT06912490
Start Date
April 15 2025
End Date
December 20 2029
Last Update
April 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children Hospital
Toulouse, France, 31059